

<b>Study</b>	<b>Outcome measure with original reference where given in paper</b>
<b>Antoniou 2006[1]</b>	Medical Research Council (MRC) dyspnoea scale[2] Cough- Dry, productive, absent (no reference) St George's Respiratory Questionnaire (SGRQ) [3, 4]
<b>King 2009[5]</b>	University of California San Diego shortness of breath questionnaire (UCSD)[6] SGRQ[7]
<b>Strieter 2004[8]</b>	Modified MRC scale (no ref) Baseline Dyspnoea Index (BDI) and Transition (endpoint) dyspnoea index (TDI) (no ref) UCSD (no ref)
<b>Jackson 2010[9]</b>	Borg dyspnoea scale (modified 10 point)[10]
<b>Zisman 2010[11]</b>	UCSD [12] Borg dyspnoea index [13] SGRQ [14] SF-36 [14] EQ-5D [15]
<b>Collard 2007[16]</b>	Borg Dyspnoea Index (no ref)
<b>Nishiyama 2008[17]</b>	BDI [18] SGRQ [19]
<b>Holland 2008[20]</b>	MRC scale (modified)[2] SF-36[7] Chronic Respiratory Disease Questionnaire (CRDQ)[7]
<b>Ozalevli 2010[21]</b>	MRC scale [22] Borg dyspnoea Index (modified) [2] SF-36 (Turkish version) [23]
<b>Rammaert 2009[24]</b>	Baseline Dyspnoea Index [25] Borg Dyspnoea Index [26] MRC scale [27] SF-36 [28] SGRQ [29] Hospital Anxiety and Depression scale [30] 7 questions in Visual Analogue Scale looking at symptoms and quality of life
<b>Kozu 2011[31]</b>	MRC scale [32] BDI & TDI [18] SF-36 version 2 (Japanese version)[33]
<b>Swigris 2011[34]</b>	Fatigue Severity Scale[35] General Anxiety Disorder-7 scale[36] Patient Health Questionnaire-8 [37] Pittsburgh Sleep Quality Index [38] SF-36 [37]
<b>King 2011[39]</b>	Baseline Dyspnoea Index Transition Dyspnoea Index [18] SF-36[40] EQ5D[41]
<b>King Jr 2008 (BUILD 1)[42]</b> <b>Raghu 2010 (2<sup>nd</sup> paper BUILD 1)[43]</b>	Borg Dyspnoea Index [26] Baseline Dyspnoea Index Transition Dyspnoea Index [18] SF-36[44] SGRQ[3]
<b>Noble 2011[45]</b>	UCSD[6]
<b>Tomioaka 2005[46]</b>	SF-36 (Japanese version) [33, 47]
<b>Demedts 2005[48]</b>	Dyspnoea Score[49] SGRQ [3]
<b>Varney 2008[50]</b>	MRC scale (no ref) SGRQ (no ref)
<b>Raghu 2008[51]</b>	Mahler dyspnoea scale (no ref) SF-36 (no ref) SGRQ[52]
<b>Krowka 2007[53]</b>	Borg Dyspnoea Index (no ref) NYHA class (no ref)
<b>Lindell 2010[54]</b>	UCSD[6] Beck Anxiety Inventory[55] Beck Depression Inventory-II[56] Perceived Stress Scale[57] SF-36[58]
<b>Hope-Gill 2003[59]</b>	Visual Analogue Scale for cough (no ref)
<b>Turner-Warwick 1980[60]</b>	4 step improvement in dyspnoea scale (no ref)
<b>Fiorucci 2008[61]</b>	20 point dyspnoea scale (as part of clinical radiologic physiologic-CRP scoring system) [49, 62]
<b>Hicks 2007[63]</b>	Borg dyspnoea index (no ref)
<b>Visca 2011[64]</b>	Borg dyspnoea index [26]
<b>Allen 2005[65]</b>	Visual Analogue Scale for dyspnoea (no ref)
<b>Hanania 1993[66]</b>	NYHA criteria (no ref)
<b>Lutherer 2011[67]</b>	Leicester Cough Questionnaire[68]
<b>Agusti 1993[69]</b>	5 point dyspnoea scale[70]
<b>Horton 2008[71]</b>	Question 2 on SGRQ (no ref) for assessment of cough
<b>Undurraga 1998[72]</b>	20 point dyspnoea scale (as part of clinical radiologic physiologic-CRP scoring system) [49]
<b>Mishra 2011[73]</b>	SGRQ (no ref)

1. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. *European Respiratory Journal*. 2006 Sep;28(3):496-504.
2. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. *Chest*. 1988 Mar;93(3):580-6.
3. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. *Respiratory Medicine*. 1991 Sep;85 Suppl B:25-31; discussion 3-7.
4. Bouros D, Psathakis K, Siafakas NM. Quality of life in interstitial lung disease. *Eur Respir Rev*. 1997;7:66-70.
5. King Jr TE, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *The Lancet*. 2009;374 (9685):222-8.
6. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. *Chest*. 1998 Mar;113(3):619-24.
7. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health-related quality of life in patients with interstitial lung disease. *Chest*. 1999 Nov;116(5):1175-82.
8. Strieter RM, Starko KM, Enelow RI, et al. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory & Critical Care Medicine*. 2004 Jul 15;170(2):133-40.
9. Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. *Lung*. [Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S.]. 2010 Apr;188(2):115-23.
10. ATS statement: guidelines for the six-minute walk test. *American Journal of Respiratory & Critical Care Medicine*. 2002 Jul 1;166(1):111-7.
11. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *New England Journal of Medicine*. 2010 12 Aug;363 (7):620-8.
12. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. *Journal of Cardiopulmonary Rehabilitation*. 2005 Nov-Dec;25(6):370-7.
13. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. *COPD*. 2005 Mar;2(1):105-10.
14. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. *Respiratory Medicine*. 2010 Feb;104(2):296-304.
15. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. *Health QualLife Outcomes*. 2007;5:70.
16. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. *Chest*. 2007;131(3):897-900.
17. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology*. 2008 May;13 (3):394-9.
18. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. *Chest*. 1984 Jun;85(6):751-8.
19. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *American Review of Respiratory Disease*. 1992 Jun;145(6):1321-7.
20. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax* [serial on the Internet]. 2008; (6): Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/697/CN-00637697/frame.html>.

21. Ozalevli S, Karaali HK, Ilgin D, et al. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Multidisciplinary Respiratory Medicine*. 2010 February;5(1):31-7.
22. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax*. 1999 Jul;54(7):581-6.
23. Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. *BMC Public Health*. 2006;6:247.
24. Rammaert B, Leroy S, Cavestri B, et al. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. [French]. *Revue des Maladies Respiratoires*. 2009;26(3):275-82.
25. Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, et al. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. *Medical Science Monitor*. 2002 Jun;8(6):CR405-10.
26. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14(5):377-81.
27. Papiris SA, Daniil ZD, Malagari K, et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. *Respiratory Medicine*. 2005 Jun;99(6):755-61.
28. Boueri FM, Bucher-Bartelson BL, Glenn KA, et al. Quality of life measured with a generic instrument (Short Form-36) improves following pulmonary rehabilitation in patients with COPD. *Chest*. 2001 Jan;119(1):77-84.
29. Ferrer M, Villasante C, Alonso J, et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. *European Respiratory Journal*. 2002 Mar;19(3):405-13.
30. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983 Jun;67(6):361-70.
31. Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. *Respiration*. 2011;81(3):196-205.
32. Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. *Br Med J*. 1959 Aug 29;2(5147):257-66.
33. Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. *J Clin Epidemiol*. 1998 Nov;51(11):1037-44.
34. Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. *Respir Care*. 2011 Jun;56(6):783-9.
35. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol*. 1989 Oct;46(10):1121-3.
36. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006 May 22;166(10):1092-7.
37. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord*. 2009 Apr;114(1-3):163-73.
38. Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989 May;28(2):193-213.
39. King TE, Jr., Brown KK, Raghu G, et al. The BUILD-3 Trial: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Of Bosentan In Idiopathic Pulmonary Fibrosis [Abstract]. *American Journal of Respiratory and Critical Care Medicine* [serial on the Internet]. 2010; (Meeting Abstracts): Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/179/CN-00758179/frame.html>.
40. Ware JE, Jr., Kosinski M, Bjorner JB, et al. User's manual for the SF-36v2TM Health Survey. 2nd edition ed. Lincoln: QualityMetric Incorporated; 2007.
41. EuroQolGroup. EuroQol- a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199-208.
42. King Jr TE, Behr J, Brown KK, et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*. 2008 01 Jan;177(1):75-81.

43. Raghu G, King Jr TE, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). *European Respiratory Journal*. 2010 January;35 (1):118-23.
44. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992 Jun;30(6):473-83.
45. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet*. 2011 May 21;377(9779):1760-9.
46. Tomioka H, Kuwata Y, Imanaka K, et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. *Respirology*. 2005 Sep;10 (4):449-55.
47. Fukuhara S, Ware JE, Jr., Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. *J Clin Epidemiol*. 1998 Nov;51(11):1045-53.
48. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *New England Journal of Medicine*. 2005;353(21):2229-43.
49. Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. *American Review of Respiratory Disease*. 1986 Jan;133(1):97-103.
50. Varney VA, Parnell HM, Salisbury DT, et al. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. *Pulmonary Pharmacology and Therapeutics*. 2008 Feb;21 (1):178-87.
51. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *American Journal of Respiratory & Critical Care Medicine*. 2008;178(9):948-56.
52. Jones PW, Spencer S, Adi S. *The St George's Respiratory Questionnaire manual, version 2*. London St George's Hospital; 2003.
53. Krowka MJ, Ahmad S, de Andrade JA, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. *Chest [serial on the Internet]*. 2007; (4): Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/705/CN-00642705/frame.html>.
54. Lindell KO, Olshansky E, Song M, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. *Heart & Lung*. 2010;39(4):304-14.
55. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol*. 1998;56:893-7.
56. Beck AT, Steer RA, Brown GK. *Beck Depression Inventory manual* New York: The Psychological Corporation, Harcourt Brace and Company; 2002.
57. Cohen S, Hoberman H. Positive events and social support as buffers of life change stress. *J Appl Soc Psychol*. 1983;13:99-125.
58. Martinez TY, Pereira CA, dos Santos ML, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. *Chest*. 2000 Jun;117(6):1627-32.
59. Hope-Gill BDM, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. *American Journal of Respiratory & Critical Care Medicine*. 2003;168(8):995-1003.
60. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. *Thorax*. 1980 Aug;35(8):593-9.
61. Fiorucci E, Lucantoni G, Paone G, et al. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. *Eur Rev Med Pharmacol Sci. [Clinical Trial Comparative Study]*. 2008 Mar-Apr;12(2):105-11.
62. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. *American Journal of Respiratory & Critical Care Medicine*. 1998 Apr;157(4 Pt 1):1063-72.
63. Hicks S, Spencer LG, Duck A, et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: Of what benefit? *Thorax*. 2007 Dec;62:A45-A6.

64. Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. *European Respiratory Journal*. 2011 Oct;38(4):987-90.
65. Allen S, Raut S, Woollard J, et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. *Palliative Medicine*. 2005;19(2):128-30.
66. Hanania NA, Thomas P. D-PENICILLAMINE IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS. *American Review of Respiratory Disease*. 1993 Apr;147(4):A589-A.
67. Lutherer LO, Nugent KM, Schoettle BW, et al. Low-dose oral interferon alpha possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. *Thorax*. 2011 May;66(5):446-7.
68. Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire? *Handb Exp Pharmacol*. 2009(187):311-20.
69. Agust, x00Ed, C., et al. Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study. *Thorax*. [Research Support, Non-U.S. Gov't]. 1993 Jan;48(1):68-9.
70. Xaubet A, Rodriguez-Roisin R, Bombi JA, et al. Correlation of bronchoalveolar lavage and clinical and functional findings in asbestosis. *American Review of Respiratory Disease*. 1986 May;133(5):848-54.
71. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. *Thorax*. [Letter]. 2008 August;63 (8):749.
72. Undurraga Pereira A, Meneses Ciuffardi M, Sabbagh P E, et al. Tratamiento de la fibrosis pulmonar idiopática con colchicina. *Rev méd Chile*. 1998;126(11):1345-53.
73. Mishra A, Bhattacharya P, Paul S, et al. An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. *Lung India*. 2011 Jul;28(3):174-9.